Reported 25 days ago
Pfizer's stock rises after surpassing Wall Street expectations for the second quarter and revising its annual forecast upwards, mainly due to effective cost-cutting measures and strong drug sales. The company aims for $4.5 billion in savings and continues to see contributions from COVID-related products as well as its recent acquisition of Padcev, which supports its revenue goals amid impending patent expirations.
Source: YAHOO